Universidad Simón Bolívar

Age-Driven Cardiovascular Risk Scores Differ Across Antiretroviral Regimens Among People Living with HIV in the Colombian Caribbean Region

Background/Objectives: People living with HIV (PLHIV) face an elevated burden of cardiovascular disease, and general-population and HIV-specific risk scores are commonly used for stratification, though data from Latin America, particularly Colombia’s Caribbean region, remain scar...

GAP2POP as a complementary hierarchical framework for aligning knowledge gaps, health priorities, evidence generation, and population influence-impact

Background Health research evaluation frameworks rarely integrate the identification of knowledge gaps and health needs, the definition of health priorities, evidence generation, the monitoring of population indicators, and the assessment of knowledge translation and population i...

Antiproteinuric Response to Finerenone in Diabetic Kidney Disease: Responder and Non-Responder Subgroup Analysis of the FINDKDLATAM Study

Background/Objectives: Albuminuria is an early marker of kidney damage and an independent predictor of adverse outcomes, making its reduction a key therapeutic goal. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has demonstrated renal and cardiovascu...

Establishment of Reference Values for Selected Spatiotemporal and Kinematic Running Parameters in Healthy Adult Recreational Runners from Barranquilla, Colombia

Background and Objectives: Running-related musculoskeletal injuries remain highly prevalent among recreational runners, and the absence of population-specific biomechanical reference values limits clinical and sports interpretation in Latin American populations. This study aimed...

Obinutuzumab Induces Histological Remission and Deep Kidney Parenchymal B-Cell Depletion in Patients with Lupus Nephritis: Exploratory Analyses of the Phase III REGENCY Trial

Objectives The REGENCY trial ( NCT04221477 ) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at Week 76 (W76) in adults with active lupus nephritis (LN). These exploratory analyses aimed to...